Rana et al
1 published a report of a girl affected by a stage IV B-cell non-Hodgkin (Burkitt) lymphoma who relapsed 8 months after the initial diagnosis and developed acute lymphoblastic leukemia. She underwent pseudoautologous bone marrow transplantation with a TBI-based regimen using stem cells from her brother, who had undergone BMT himself 10 years earlier from the same sister, for the treatment of acute myeloid leukemia (AML) in first complete remission (CR). The case report ended with the statement that the patient was well 8 months after transplant, which, given the characteristics of donor and recipient, could be considered autologous.
Unfortunately, following this case report, the leukemia recurred in the girl's bone marrow and in multiple bone sites 9 months post transplant. The relapse was also documented at a molecular level by PCR amplification of patient-specific IgH gene rearrangement. The MRI showed bilateral lesions in the pelvis and femur. Consequently, the girl began a 4-week chemotherapy cycle which induced a third bone marrow remission; after 4 months of intensive consolidation therapy, molecular remission was also achieved. The patient's clinical condition, including cachexia, prolonged aplasia and active HBV infection, precluded an allogeneic BMT, so a second pseudoautologous transplant was performed 14 months after the first one. The conditioning regimen was busulfan (16 mg/kg in 4 days), cyclophosphamide (100 mg/kg in 2 days) and etoposide (50 mg/kg in one day), followed by infusion of bone marrow stem cells (nucleated cells ¼ 5.53 Â 10 8 /kg, CD34 þ cells ¼ 3.83 Â 10 6 /kg) collected from the same donor. On day þ 18 the myeloid series engrafted (PMN4500 Â 10 6 /l), and on day þ 51 platelets exceeded 20 Â 10 9 /l. During hospitalization, the patient sustained grade II mucositis, a staphylococcal infection of the central venous catheter (CVC) and pneumonitis, which proved to be fungal in origin when analyzed with the CT scan; this was successfully treated with amphotericin-B for 4 weeks. The patient presented further CVC infections at 3 and 11 months after the second transplant, after which the catheter was removed. At 36 months after the second transplant, the girl's bone marrow was normocellular and was consistent with CR. A radiological examination showed the persistence of high density areas in the pelvic bones and both femora, which were interpreted as sclerotic areas not due to active leukemia.
At her most recent clinic assessment, the patient had early cataracts bilaterally and a moderate pulmonary restrictive syndrome. A cardiac ultrasound showed a normal ejection fraction (60%). Thyroid, liver and kidney function tests were normal.
The interest in this case lies in the fact that the patient, affected by a particularly aggressive malignant disease, may actually be considered 'cured' after two transplants, which, given the characteristics of the donor/recipient pair, can be classified as autologous BMTs. For this patient, the treatment options after her second relapse included a pseudoautologous and an allogeneic unrelated BMT: the latter was expected to be more effective but also more toxic, 2, 3 given the long-lasting chemotherapy delivered as first-and second-line treatment and also because of the precarious clinical condition of the patient.
Moreover, given the aggressiveness of the disease, we felt that the time required to complete the search for an unrelated donor would have exposed the patient to a greater risk of disease relapse. Therefore, after the failure of the first transplant incorporating TBI-based conditioning, the girl underwent a second autologous transplant with busulfan.
4 Despite a series of infectious complications particularly in the first 100 days post second transplant, the patient is now 3.5 years post second transplant, is in good health (Lansky 100%) and in bone and marrow remission, which allows us to say that she is cured.
In summary, we feel that in our case, where the graftversus-leukemia effect was unlikely, the therapeutic success was probably due to the antileukemic efficacy of the conditioning regimen, which was capable of eradicating the disease in the bone marrow and in the skeleton.
5,6 This result should encourage us to promote the value of highdose busulfan as part of the transplant conditioning regimen used in aggressive oncohematological diseases predominantly localized in the bone, where this drug can reach a high concentration as demonstrated in relapsed osteosarcoma or NHL. 
